Inarigivir ammonium manufacturers
- Inarigivir ammonium
-
- $52.00 / 1mg
-
2026-02-02
- CAS:2172788-92-8
- Min. Order:
- Purity: 99.91%
- Supply Ability: 10g
|
| | Inarigivir ammonium Basic information |
| Product Name: | Inarigivir ammonium | | Synonyms: | Inarigivir ammonium;ORI-9020 ammonium;SB-9200 ammonium;inhibit,HCV,HBV,RIG-I,Huh7,SB9000,ORI-9020,SB 9000,SB-9000,antiviral,Inarigivir ammonium,Inhibitor,ORI 9020,Hepatitis B virus,Inarigivir,ORI9020;Inarigivir (ammonium salt) | | CAS: | 2172788-92-8 | | MF: | C20H29N8O10PS | | MW: | 604.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2172788-92-8.mol |  |
| | Inarigivir ammonium Chemical Properties |
| solubility | DMSO : 100 mg/mL (165.42 mM; Need ultrasonic) | | form | Solid | | color | White to light yellow |
| | Inarigivir ammonium Usage And Synthesis |
| Uses | Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses[1][2]. | | Biological Activity | Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as an RIG-I agonist to activate cellular innate immune responses[1][2].
Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B[2].
Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[1]. | | in vivo | Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[1]. | Animal Model: | Mice[1] | | Dosage: | 100 mg/kg. | | Administration: | IP, daily. | | Result: | Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control. |
| | References | [1]. Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20. [2]. Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos(t)ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro. |
| | Inarigivir ammonium Preparation Products And Raw materials |
|